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ABSTRACT Benralizumab is an interleukin-5 receptor α-directed cytolytic monoclonal antibody
approved in several countries for the add-on maintenance treatment of patients with severe eosinophilic
asthma aged 12 years and older. In the 28-week Phase III ZONDA trial (ClinicalTrials.gov identifier:
NCT02075255), benralizumab produced a median 75% reduction from baseline in oral corticosteroid
(OCS) dosage (versus 25% for placebo) while maintaining asthma control for patients with OCS-
dependent severe asthma. This manuscript presents the detailed protocol for the Phase IIIb PONENTE
(ClinicalTrials.gov identifier: NCT03557307), a study that will build on the findings from ZONDA.
As the largest steroid-sparing study undertaken in severe asthma, PONENTE has a faster steroid
tapering schedule for prednisone dosages ⩾7.5 mg·day−1 than previous studies, and it includes an
evaluation of adrenal insufficiency and an algorithm to taper OCS dosage when prednisone dosage is
⩽5 mg·day−1. It also has a longer maintenance phase to assess asthma control for up to 6 months after
completion of OCS tapering.
The two primary endpoints are whether patients achieve 100% reduction in daily OCS use and whether
patients achieve 100% reduction in daily OCS or achieve OCS dosage ⩽5 mg·day−1, if adrenal insufficiency
prevented further reduction, both sustained over ⩾4 weeks without worsening of asthma. Safety and
change from baseline in health-related quality of life will also be assessed.
PONENTE should provide valuable guidance for clinicians on tapering OCS dosage, including the
management of adrenal insufficiency, following benralizumab initiation for the treatment of patients who
are OCS-dependent with severe, uncontrolled eosinophilic asthma.
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Introduction
Asthma is a chronic disease that affects more than 339 million people worldwide [1]. It is associated with
airway inflammation and hyperresponsiveness, together with reversible airway obstruction [2, 3].
Approximately 10% of patients with asthma have severe disease, defined by international guidelines
(Global Initiative for Asthma (GINA)/European Respiratory Society/American Thoracic Society) as disease
that requires treatment with high-dosage inhaled corticosteroids (ICSs) plus bronchodilators with or
without oral corticosteroids (OCSs) to control symptoms, or disease that remains uncontrolled despite this
treatment [3, 4]. In different studies, 44–87% of patients with severe asthma are estimated to have
uncontrolled disease (GINA classification or similar) [4]. These patients experience poor symptom control,
frequent severe and potentially life-threatening exacerbations or fixed airflow obstruction, symptoms which
can have devastating impacts on health-related quality of life (HRQOL) [3, 5].
OCSs are used to treat asthma exacerbations and as maintenance treatment for patients with severe,
uncontrolled eosinophilic asthma at risk of repeated severe exacerbations [3, 6]. Of patients with severe
asthma, an estimated 32–45% rely on recurrent or maintenance OCS use [7, 8]. Not only does long-term
OCS use have substantial consequences, but cumulative dosing from recurrent OCS use in the shorter
term is also associated with adverse events (AEs) including osteoporosis, fractures, hyperglycaemia,
diabetes, cardiovascular disease, anxiety and immunosuppression [5, 6, 9, 10]. Furthermore, long-term
OCS use can suppress the hypothalamic–pituitary–adrenal (HPA) axis, occasionally resulting in adrenal
insufficiency (AI) [11, 12]. These AEs have a further negative impact on the HRQOL of patients with
severe asthma and can also worsen other comorbidities.
Benralizumab is an interleukin-5 receptor α-directed cytolytic monoclonal antibody that induces direct,
rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated
cytotoxicity [13, 14]. Benralizumab is approved in several countries, including the United States, where it
is indicated for the add-on maintenance treatment of patients with severe eosinophilic asthma aged
12 years and older [15]. In the Phase III SIROCCO (ClinicalTrials.gov identifier: NCT01928771) and
CALIMA (ClinicalTrials.gov identifier: NCT01914757) trials, benralizumab in combination with
high-dosage ICSs plus long-acting β2-agonists (LABAs) significantly reduced asthma exacerbations and
improved lung function and disease control for patients with severe, uncontrolled asthma and blood
eosinophil counts ⩾300 cells·μL−1 versus placebo [16, 17].
In the Phase III ZONDA trial (ClinicalTrials.gov identifier: NCT02075255), OCS dosage was reduced with
benralizumab treatment from baseline to Week 28 by a median of 75% compared with a 25% reduction for
placebo [18]. Of patients eligible for a 100% reduction in OCS dosage (who were receiving ⩽12.5 mg of
prednisone per day at baseline), 52% and 56% of patients receiving benralizumab every 4 weeks (Q4W) and
every 8 weeks (Q8W; first three doses Q4W), respectively, had a 100% reduction in their OCS dosage by
Week 28 compared with a 19% reduction for placebo [18]. However, because of the relatively short OCS
tapering timeline in ZONDA (28 weeks), the potential for down-titration for patients receiving baseline
prednisone >12.5 mg·day−1 was not fully studied. The PONENTE trial (ClinicalTrials.gov identifier:
NCT03557307) builds on ZONDA and other OCS-sparing studies. PONENTE is a Phase IIIb trial designed
to evaluate the efficacy and safety of tapering OCS use after initiation of benralizumab treatment for adult
patients with severe, uncontrolled asthma with eosinophilic inflammation. PONENTE has a faster steroid
tapering schedule for prednisone dosages ⩾7.5 mg·day−1 (when patients are not at risk of AI) than previous
studies, and it includes an evaluation of AI and an algorithm to specifically taper OCS dosage when
prednisone is ⩽5 mg·day−1, and when patients are potentially at risk of developing AI. It also has a longer
maintenance phase to assess the ability to maintain the achieved OCS reduction and the impact of OCS
reduction on asthma control for up to 6 months after reduction and completion of OCS tapering. In this
manuscript, we describe the PONENTE protocol in detail, including the steroid-tapering schedule.
Study methodology
PONENTE is an ongoing multicentre, open-label, Phase IIIb study that aims to enrol 600 patients in
approximately 180 clinical centres worldwide. Participating countries include Argentina, Belgium, Brazil,
Canada, Colombia, Denmark, France, Germany, Italy, Mexico, Poland, Russian Federation, Spain, Sweden,
Taiwan, United Kingdom and the United States. The PONENTE study design and future implementation
are guided by an expert scientific committee that, in addition to respiratory disease clinical experts,
includes an endocrinologist. The trial began enrolling on August 1, 2018, with a planned study completion
projected or approximately in October 2020.
Study participants
Eligible patients are men and women aged ⩾18 years with physician-diagnosed asthma requiring
high-dosage ICS (fluticasone propionate or equivalent >500 μg·day−1) plus LABA for ⩾6 months before
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enrolment. They are required to receive long-term OCS therapy (prednisone ⩾5 mg·day−1) for
⩾3 continuous months and a stable OCS dosage for ⩾4 weeks before enrolment. Alternate OCS dosing
(e.g. every other day), other dosing frequencies, and OCS therapy other than prednisone/prednisolone are
allowed provided the average daily dose is equivalent to ⩾5 mg of prednisone and the patient is switched
to daily prednisone/prednisolone at Visit 1. Prednisone/prednisolone was selected because it is the most
common OCS used in clinical practice. Patients must also have documented blood eosinophil counts
⩾150 cells·μL−1 at enrolment or ⩾300 cells·μL−1 in the 12 months before enrolment.
Patients will be excluded if they have any current, clinically important pulmonary disease other than
asthma or a previous diagnosis for a pulmonary or systemic disease other than asthma that is associated
with elevated peripheral blood eosinophil counts. Patients receiving any of the following treatments within
30 days will not be eligible for inclusion: macrolides, antivirals, azole therapies, immunosuppressants,
blood products, immunoglobulin, live attenuated vaccines, and lipoxygenase inhibitors. They will also be
excluded if they have any comorbidities requiring OCS treatment. Full inclusion and exclusion criteria are
included in the appendix. Patients will be allowed to continue their usual asthma controller medication
during the study.
Independent ethics committees at each study centre will approve the clinical study protocol. The national
regulatory authorities have approved the clinical study protocol or received a notification per local
regulations. All patients will be required to provide written informed consent before participation. The
study will be conducted in accordance with the principles of the Declaration of Helsinki, which is
consistent with the International Conference on Harmonisation/Good Clinical Practice, as well as
applicable regulatory requirements and AstraZeneca company policy on bioethics and human biologic
samples.
Study design
PONENTE consists of an enrolment period and an open-label treatment period (figure 1). During the
enrolment period, patients who are receiving OCS other than prednisone/prednisolone will be switched to
this treatment. The open-label benralizumab treatment period consists of a 4-week induction phase, a
variable OCS tapering phase, and a 24–32-week maintenance phase. No adjustments to OCS dosage are
permitted during the 4-week induction phase.
Treatment
Starting at Week 0, patients will receive benralizumab 30 mg by subcutaneous injection Q4W for the first
three doses and Q8W thereafter. Patients will receive benralizumab at the first induction phase visit and
throughout the induction phase, OCS tapering phase, and maintenance phase. Patients will continue their
baseline ICS plus LABA maintenance therapy during the study.
Oral corticosteroid tapering protocol
The OCS tapering phase will begin at Week 4. During this phase, OCS dosages will be reduced by 5 mg
either weekly or every 2 weeks (Q2W) or by 2.5 mg Q2W or Q4W, depending on the baseline OCS
dosage, until a dosage of 5 mg·day−1 is achieved (figure 2). The speed of OCS tapering will also depend on
the patient’s degree of asthma control, as assessed by the investigator, based on patient-reported symptom
information, weekly Asthma Control Questionnaire 6 (ACQ-6) scores, compliance with maintenance
asthma therapy, and occurrence of an asthma exacerbation. For prednisone dosages <5 mg·day−1, if the
exact dosage is unavailable, daily dosage can be achieved by dosing every other day, where the daily dosage
is the average of 2 days.
For patients who reduce to OCS dosages of 5 mg·day−1, a HPA axis integrity evaluation for AI will be
performed after 4 weeks at this dosage (figure 3). For patients receiving an OCS dosage of 5 mg·day−1 at
baseline, HPA axis integrity evaluation will be performed 4 weeks after the first dose of benralizumab,
prior to the OCS reduction phase. The HPA axis integrity evaluation will consist of a morning (between
8 and 9 am) serum cortisol concentration measurement 24 h after the last OCS dose and at least 12 h after
the last ICS dose. An adrenocorticotropic hormone (ACTH) stimulation test (i.e. Synacthen®,
Cortrosyn™) will be performed within 1 week of morning cortisol test results for patients with cortisol
concentrations indicating partial AI (range, 100–350 nmol·L−1; normal concentration >350 nmol·L−1;
complete AI concentration <100 nmol·L−1). Patients will be required to withhold OCS use for ⩾24 h
before testing and withhold ICS/LABA use on the morning of testing. Patients will receive an intravenous
injection of tetracosactide 250 μg, with serum cortisol concentrations measured before and 30 min after
injection (further details of the ACTH testing procedure are provided in the appendix). For ACTH testing,
a cortisol concentration >450 nmol·L−1 will be considered normal, and concentrations 250–450 nmol·L−1
and <250 nmol·L−1 will be considered partial and complete AI, respectively. For patients without evidence
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of AI, as assessed by morning cortisol or ACTH stimulation test, OCS dose will be reduced by 2.5 mg
Q4W (figure 2). For those patients with partial AI or with symptoms suggestive of AI in the absence of
abnormal AI tests, OCS tapering will follow a speed of 1 mg Q4W. However, in case of complete AI, no
further tapering in the OCS dosage will be allowed. Further OCS dosage reduction strategy will depend on
results of the cortisol and ACTH tests. For patients with partial or complete AI, additional HPA axis
integrity evaluations will be performed to monitor status.
Patients who completely withdraw OCS use or are maintained on the lowest OCS dosage possible without
occurrence of AI or loss of asthma control will enter the maintenance phase, during which initiation or
increase in OCS dosage is allowed in case of asthma worsening. A follow-up visit will be conducted
12 weeks after the last dose of benralizumab, discontinuation of benralizumab, or discontinuation from the
study.
OCS tapering can be interrupted if patients experience asthma worsening or asthma exacerbation that
requires increased OCS treatment (⩾3 consecutive days), hospitalisation, or emergency room admission.
After completion of the OCS/bolus burst to treat an exacerbation, investigators can perform one of the
following options for at least 2 weeks: 1) return patients to a one-step greater dosage (or more if
OCS
reduction phase#
Enrolment
period
Induction
phase
(stable OCS)
Maintenance phase
(~24–32 weeks)
Follow-up
period
(4 weeks)
First
benralizumab 
dose
Second
benralizumab 
dose
4 weeks Variable duration depending
on individual baseline OCS dosage
Benralizumab Q8W 
for three doses
Follow-up contact
(12 weeks after 
last benralizumab 
dose)Benralizumab 30-mg treatment period
(Q4W for the ﬁrst three doses, then Q8W until EOT)
EOT visit (8 weeks 
after last 
benralizumab dose)
FIGURE 1 PONENTE study design. EOT: end of treatment; OCS: oral corticosteroid; Q4W: every 4 weeks; Q8W: every 8 weeks. #: guided by schema
of OCS reduction defined in the study protocol.
>5–≤7.5 mg·day–1
>20 mg·day–1
Baseline OCS dosage
5 mg·day–1 Q1W 5 mg·day–1 Q2W
5 mg·day–1 Q2W
2.5 mg·day–1 Q2W
2.5 mg·day–1 Q2W
2.5 mg·day–1 Q4W
20 mg·day–1 10 mg·day–1 7.5 mg·day–1 5 mg·day–1
2.5 mg·day–1 Q4W
2.5 mg·day–1 Q2W 2.5 mg·day–1 Q4W
2.5 mg·day–1 Q4W
OCS reduction until reaching a prednisone dosage of 
>10–≤20 mg·day–1
>7.5–≤10 mg·day–1
FIGURE 2 OCS down-titration schema until dosage of 5 mg·day−1 is reached, without worsening of asthma. OCS: oral corticosteroid; Q1W: every
week; Q2W: every 2 weeks; Q4W: every 4 weeks.
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Normal
>350 nmol·L–1
Continue
down-titration
(2.5 mg Q4W)
Repeat test 
2 months later
Continue
down-titration
(2.5 mg Q4W)
Delay titration 
and repeat test 
3 months later
Complete AI
<100 nmol·L–1
Delay titration 
and repeat test 
3 months later
Morning cortisol (08:00–09:00 h)
Prednisone dosage
5 mg·day–1
Partial AI
(intermediate values)
100–350 nmol·L–1
ACTH stimulation
test (i.v.)
(0 and 30 min)
Partial AI
(intermediate values)
250–450 nmol·L–1
Complete AI
<250 nmol·L–1
Normal
>450 nmol·L–1
Slow titration
(1 mg Q4W)
FIGURE 3 Hypothalamic–pituitary–adrenal axis evaluation and oral corticosteroid down-titration schema from prednisone dosage of 5 mg·day−1.
ACTH: adrenocorticotropic hormone; AI: adrenal insufficiency; i.v.: intravenous; Q4W: every 4 weeks.
>20 mg·day–1 5 mg·day–1 Q4W
5 mg·day–1 Q4W
2.5 mg·day–1 Q4W
2.5 mg·day–1 Q4W
2.5 mg·day–1 Q4W
10 mg·day–1 5 mg·day–1
>10–≤20 mg·day–1
>5–≤10 mg·day–1
OCS reduction until reaching a
prednisone dosage of 
FIGURE 4 Rescue down-titration after recovery from asthma exacerbation or deterioration. OCS: oral
corticosteroid; Q4W: every 4 weeks.
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considered necessary by the investigators) than was prescribed when the exacerbation occurred, or
2) maintain the patient on the same, stable OCS dosage before continuing OCS tapering upon recovery
from the exacerbation.
Patients who have a first asthma exacerbation or asthma deterioration will be allowed to continue OCS
reduction after recovery on a slower schedule, similar to the ZONDA trial design (Q4W), based on the
investigators’ judgement (figure 4). In the case of a second asthma exacerbation or worsening, OCS
tapering will cease, and patients will continue their same dosages or return to a one-step greater dosage
than what was prescribed when the exacerbation occurred.
The lowest OCS dosage that is stable during a 4-week period and prevents asthma exacerbation or asthma
worsening without increasing OCS dosage will be considered the final OCS dosage of the OCS tapering
phase. The patient will enter the maintenance phase with this dosage.
Asthma control and health-related quality of life assessments
ACQ-6 will be completed every week from the start of the induction phase (Week 0) to the end of
treatment. Data will be collected via an electronic patient-reported outcomes device. ACQ-6 is scored on a
scale from 0 to 6, with smaller numbers indicating better asthma control [19, 20]. St. George’s Respiratory
Questionnaire (SGRQ) will be completed at the start of the induction phase and at the end of treatment or
discontinuation. SGRQ is scored on a scale from 0 to 100, with greater scores indicating greater
impairment [21, 22]. Details of ACQ-6 and SGRQ are provided in the appendix.
Safety assessments
Safety will be monitored at each study centre from enrolment to the follow-up visit at the end of the study.
Additionally, glucocorticoid toxicity index (GTI) will be measured at the induction phase, when patients
achieve an OCS dosage of ⩽5 mg·day−1, and at the end of treatment or discontinuation [23]. The
composite GTI measures common glucocorticoid toxicities that are sensitive to differing cumulative
glucocorticoid dosages over a typical clinical trial period. Details of the GTI measurement are provided in
the appendix.
Outcome measures
PONENTE has two primary efficacy endpoints. The first is whether patients achieve a 100% reduction in
daily OCS dosage that is maintained for ⩾4 weeks without asthma worsening. The second is whether
patients achieve 100% reduction in daily OCS dosage or a daily OCS dosage ⩽5 mg, if the reason for no
further OCS reduction is AI, that is maintained for ⩾4 weeks without asthma worsening.
Secondary efficacy endpoints are included to allow investigators to assess asthma control during the OCS
tapering phase and the sustained reduction of daily OCS dosage while maintaining asthma control for
approximately 6 months after the end of OCS tapering (maintenance phase) for patients treated with
benralizumab. The effect of this treatment schedule on patients’ asthma control and HRQOL will also be
evaluated. Assessments will include additional measures of OCS reduction during both the OCS tapering
and maintenance phases, and improvements in ACQ-6 and SGRQ scores. Exploratory outcomes will
include the association of common and rare genomic variants and key blood/serum biomarker parameters
with patients’ response to treatment and OCS tapering, as well as change in baseline blood eosinophil
counts during benralizumab treatment.
Safety outcomes will be the incidence of complete AI, annualised severe asthma exacerbation rate,
annualised rate of severe asthma exacerbations leading to hospitalisation or emergency department visit,
AEs, severe AEs, GTI, laboratory parameters and vital signs.
Statistical analysis
As there is no predefined hypothesis to statistically test in this study, the sample size is based on the ability
to provide sufficient precision in point estimates, both in the full analysis set (FAS) and prespecified
subpopulations. We estimate that a total sample size of 600 patients is required to provide sufficient
precision. For the FAS, a sample size of 600 patients is expected to provide 95% confidence intervals (CI)
extending 4.1% around the point estimate for a 50% observed success rate. For the primary outcome, the
observed percentage of patients who successfully reduce OCS dosage, the expected success rate is ⩾50%.
An interim review is included to re-assess the sample size.
Efficacy and safety analyses will be performed on the FAS, which will include all patients who received any
dose of benralizumab. The study will be assessed descriptively. The Clopper–Pearson method will be used
to determine the CI for the primary endpoints.
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TABLE 1 Comparison of PONENTE study features with published oral corticosteroid (OCS)-sparing studies of other biological treatments for severe asthma
Study name Study type Trial duration Patients Biologic OCS inclusion criteria OCS tapering
Time frame Dosage reduction
PONENTE
(ongoing)
Open-label,
single-arm
>36 weeks (variable
personalised OCS
tapering period) +
4 weeks follow-up
Aim: ∼600 Benralizumab ⩾5 mg·day−1 of prednisone
(or equivalent)
Dose-reduction phase:
variable depending on
baseline OCS dosage
Maintenance phase:
∼24–32 weeks
Follow-up: 4 weeks
(Week 36)
OCS dosages will be reduced by 5 mg
either weekly or every 2 weeks or by
2.5 mg every 4 weeks depending on
baseline OCS use/loss of asthma control
until reaching ⩽5 mg·day−1
Following 4 weeks at ⩽5 mg·day−1,
further OCS reduction depends on
cortisol concentration and AI status
(evaluated by HPA axis integrity)
assessed by ACTH stimulation testing
ZONDA [18] RCT 28 weeks + 8 weeks
follow-up
220 Benralizumab 7.5–40.0 mg·day−1 of
prednisone (or equivalent)
5–35 mg·day−1 of
prednisone (or equivalent)
Dose-reduction phase:
20 weeks (Week 4–24)
Maintenance phase:
4 weeks
Follow-up: 8 weeks
(Week 36)
OCS dosage reduced by 2.5–5 mg·day−1
every 4 weeks (until reaching a dosage of
7.5 mg·day−1, then further reduced to
5 mg·day−1, 1.25 mg·day−1, and
0 mg·day−1; only patients with OCS
dosage of ⩽12.5 mg·day−1 at the end of
the run-in phase were eligible for a 100%
dose reduction)
SIRIUS [28] RCT 24 weeks 135 Mepolizumab 5–35 mg·day−1 of
prednisone (or equivalent)
Run-in optimisation
phase: 3–8 weeks
Dose-reduction phase:
16 weeks (Week 4–20)
Maintenance phase:
4 weeks (Week 24)
Run-in OCS optimisation phase: OCS
reduced weekly until asthma worsening
Dose-reduction phase: OCS dosage
reduced by 1.25–10 mg·day−1 every 4
weeks (based on asthma control and
symptoms of AI); reduction only allowed
for patients with stable ACQ-5 scores and
for whom the investigator deemed
appropriate
VENTURE [29] International
RCT
24 weeks 210 Dupilumab 5–35 mg·day−1 of
prednisone (or equivalent)
Dose-reduction phase:
16 weeks (Week 4–20)
Maintenance phase:
4 weeks
Follow-up: 12 weeks
OCS dosage reduced every 4 weeks
(protocol-specified algorithm; reduction
range 2.5–25 mg·day−1, depending on
baseline OCS dosage); no dose
adjustments allowed after Week 20
RCT: randomised controlled trial; AI: adrenal insufficiency; HPA: hypothalamic–pituitary–adrenal; ACTH: adrenocorticotropic hormone; ACQ-5: five-item Asthma Control Questionnaire-5.
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Discussion
Systemic corticosteroids, usually in the form of OCS, have been the mainstay of treatment for severe
asthma and asthma exacerbations for more than 50 years [20]. They continue to be used despite
well-known related AEs and associated health care costs [10, 24]. A United Kingdom study reported that
>90% of patients with severe asthma have at least one comorbidity associated with OCS use [25]. This
contributes to an estimated 45% of patients who are non-adherent to prescribed OCS and therefore at risk
of exacerbations in the absence of alternative prescriptions [25, 26]. With the introduction of biologics for
the treatment of asthma, there is an opportunity for less reliance and minimisation of long-term OCS use
to prevent exacerbations [5].
Long-term OCS use can suppress the HPA axis, preventing endogenous cortisol production and leading to
AI [11, 12]. OCS-induced AI persists for 1 week after stopping OCS treatment for 26–49% of patients and
can continue for months for some patients [11, 12]. AI symptoms are non-specific and include fatigue and
nausea, but they can also be fatal in physiologically stressful situations (e.g. surgery, bodily injury, or severe
systemic infections). It is therefore important to monitor patients during OCS tapering, and up to
6 months following withdrawal from long-term OCS use, particularly once patients reach a physiological
dosage (i.e. prednisone 5 mg·day−1) [27]. Several targeted biologic therapies are now available for patients
with severe and OCS-dependent asthma, but an established methodology for the safe tapering of OCS
dosage following biologic initiation has yet to be confirmed.
The PONENTE study will investigate the potential for tapering the use of maintenance OCS following
benralizumab initiation for patients with severe eosinophilic asthma who are OCS-dependent. The study
design and future implementation are guided by an expert scientific committee that includes an
endocrinologist. A protocol for OCS tapering, including reduction to less than the physiological dosage of
prednisone 5 mg·day−1 or equivalent, is included in the study design. A key element of the PONENTE
study is the effectiveness of benralizumab for asthma control during rapid OCS tapering, while managing
the signs and symptoms of AI. This will be determined primarily by the ability to completely withdraw
OCS without worsening of asthma symptoms or to reach the lowest OCS dosage possible, if further OCS
reduction is prevented by the presence of AI (as measured by cortisol concentrations) or in case of
inadequate asthma control.
The PONENTE study has several advantages over previous studies on OCS reduction following the
initiation of biologic therapy (table 1). Compared with published studies, PONENTE has a personalised
OCS tapering schedule that allows for more rapid OCS tapering and depends on baseline OCS dosage and
degree of asthma control. In addition, it contains a detailed safety methodology for AI monitoring during
OCS reduction to <5 mg·day−1. It also has a significantly longer maintenance phase (approximately
24–34 weeks versus 4 weeks for published studies of other biologics), during which the efficacy and safety
of benralizumab treatment following complete elimination of OCS (or lowest possible dosage, if AI
prevented further reduction) will be evaluated comprehensively. Study limitations include the lack of a
control group and an OCS adjustment phase.
With more widespread biologic use, it is important to have guidelines in place to ensure safe and effective
OCS tapering after effective biologic therapy initiation. The PONENTE study will provide valuable
guidance for clinicians on tapering OCS dosage, including how quickly OCS can be tapered and the
management of AI, following benralizumab initiation for the treatment of OCS-dependent patients with
severe, uncontrolled eosinophilic asthma. The results will aim to direct future clinical practice on OCS
tapering following initiation of biologics and how to screen for and manage AI, thus potentially driving
guideline changes.
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